CA 19-9 is a tumor-linked antigen which is usually elevated in pancreatic cancers.
A research article published in October 28 problem of the World Journal of Gastroenterology addresses this association. The research group led by Dr Oya Uygur-Bayramicli from Istanbul examined 76 type 2 diabetics and matched them with control topics of the same age group and gender to get dependable comparisons. Ca 19-9 levels were statistically considerably higher in the diabetic group but there is not any case of pancreatic tumor in that group, that was confirmed with the help of abdominal CT. One conclusion reported by the researchers is that diabetes could be recognized as the last step of chronic pancreatitis with the brand new developing principles of pathogenesis and that the elevation of Ca 19-9 is due to chronic pancreatitis and not to pancreatic cancer.The shown pre-clinical research newly, performed in collaboration with Professor Don M. Further, immediate delivery to the CNS resulted in robust silencing of the huntingtin gene mRNA, extending presented pre-medical data previously. This silencing effect was achieved at considerable distances from the infusion site, a significant stage towards translating this delivery strategy from animal versions to the larger human brain. Additional pre-clinical studies showed ALN-HTT to be well tolerated following constant direct CNS administration over a period of approximately a month.D., Director of CNS Medication Therapy R&D at Medtronic.